Floatz logo

Therapeutic Asset Ratings

8,586 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Carboplatin
Locally Advanced and Metastatic Solid Tumors
Shanghai Runshi Pharmaceutical Technology Co., LtdP1/2B (60)
Carfilzomib
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
PfizerP1/2B (60)
cc-5013
Brain and Central Nervous System Tumors
Institut CurieP1/2B (60)
cc-5013
Recurrent Lymphoplasmacytic Lymphoma
Yazeed SawalhaP1/2B (60)
cd19-ucart
T Cell Lymphoma
Beijing GoBroad HospitalP1/2B (60)
Cediranib
AIDS-related Peripheral/Systemic Lymphoma
National Cancer Institute (NCI)P1/2B (60)
Cediranib
Recurrent Squamous Cell Carcinoma of the Nasopharynx
AIDS Malignancy ConsortiumP1/2B (60)
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Medical Oncology
Eisai Inc.P1/2B (60)
CIS-DIAMMINEDICHLOROPLATINUM II
Urethra Cancer
Jonsson Comprehensive Cancer CenterP1/2B (60)
Cyclophosphamide
Adult Anaplastic Astrocytoma
University of Alabama at BirminghamP1/2B (60)
Cytosin-Arabinosid
High-risk Tumor
Kura Oncology, Inc.P1/2B (60)
DPC-A69448
Hemophilia B With Inhibitor
Hangzhou Gensciences Biopharmaceutical Co., Ltd.P1/2B (60)
Durvalumab
Advanced Solid Tumours
AstraZenecaP1/2B (60)
Eloxatin
Biliary Tract Cancer (BTC)
Zhejiang Cancer HospitalP1/2B (60)
Enoxaparin
Pulmonary Embolism
Medical University of GdanskP1/2B (60)
FILGRASTIM
Adenocarcinoma of the Pancreas
General Oncology, Inc.P1/2B (60)
FLUTICASONE
Adenocarcinoma of the Pancreas
Barbara Ann Karmanos Cancer InstituteP1/2B (60)
FLUTICASONE
Stage III Pancreatic Cancer
Barbara Ann Karmanos Cancer InstituteP1/2B (60)
gc101
Adverse Drug Event
Shanghai Juncell TherapeuticsP1/2B (60)
Irinotecan
Cancer Pediatric
Australian & New Zealand Children's Haematology/Oncology GroupP1/2B (60)
Irinotecan
Recurrent Lymphoepithelioma of the Nasopharynx
National Cancer Institute (NCI)P1/2B (60)
Irinotecan
Recurrent Squamous Cell Carcinoma of the Nasopharynx
AIDS Malignancy ConsortiumP1/2B (60)
Obinutuzumab
B-cell Lymphoid Malignancies
BeOne MedicinesP1/2B (60)
Pelareorep
Recurrent Plasma Cell Myeloma
University of Southern CaliforniaP1/2B (60)
Pembrolizumab
Advanced Solid Tumor Malignancy
Kling Biotherapeutics B.V.P1/2B (60)
Showing 26 to 50 of 8,586 assets
PreviousPage 2 of 344Next